Recent advances in developing bioorthogonally activatable photosensitizers for photodynamic therapy

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL
Shuyi Ning , Yuanyuan Yao , Xinchi Feng , Yulin Tian
{"title":"Recent advances in developing bioorthogonally activatable photosensitizers for photodynamic therapy","authors":"Shuyi Ning ,&nbsp;Yuanyuan Yao ,&nbsp;Xinchi Feng ,&nbsp;Yulin Tian","doi":"10.1016/j.ejmech.2025.117672","DOIUrl":null,"url":null,"abstract":"<div><div>Photodynamic therapy (PDT) is a promising and powerful cancer therapeutic modality, which can generate cytotoxic reactive oxygen species (ROS) from light-irradiated photosensitizers (PSs) to eradicate tumors. To overcome the drawbacks of currently used PSs, researchers have leveraged the advantages of bioorthogonal reactions to design diverse bioorthogonally activatable photosensitizers with excellent tumor selectivity, high ROS generation controllability, and low adverse effect for effective antitumor photodynamic therapy. In this review, we comprehensively summarize and highlight the recent advances in the development of bioorthogonally activatable photosensitizers, including the structure types, designing strategies, activation patterns, photophysical properties, ROS generation efficiency, <em>in vitro</em> and <em>in vivo</em> activities, biological applications, and limitations. We also provide directions and perspectives to address the therapeutic challenges of bioorthogonally activatable photosensitizers for promoting clinical applications. We believe that the principles summarized here will offer useful references for further development of next-generation advanced intelligent photosensitizers and related strategies to realize precise and efficient tumor treatment in the future.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"291 ","pages":"Article 117672"},"PeriodicalIF":6.0000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425004374","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Photodynamic therapy (PDT) is a promising and powerful cancer therapeutic modality, which can generate cytotoxic reactive oxygen species (ROS) from light-irradiated photosensitizers (PSs) to eradicate tumors. To overcome the drawbacks of currently used PSs, researchers have leveraged the advantages of bioorthogonal reactions to design diverse bioorthogonally activatable photosensitizers with excellent tumor selectivity, high ROS generation controllability, and low adverse effect for effective antitumor photodynamic therapy. In this review, we comprehensively summarize and highlight the recent advances in the development of bioorthogonally activatable photosensitizers, including the structure types, designing strategies, activation patterns, photophysical properties, ROS generation efficiency, in vitro and in vivo activities, biological applications, and limitations. We also provide directions and perspectives to address the therapeutic challenges of bioorthogonally activatable photosensitizers for promoting clinical applications. We believe that the principles summarized here will offer useful references for further development of next-generation advanced intelligent photosensitizers and related strategies to realize precise and efficient tumor treatment in the future.

Abstract Image

Abstract Image

光动力治疗用生物正交活化光敏剂的研究进展
光动力疗法(PDT)是一种很有前途和强大的癌症治疗方式,它可以从光敏剂(ps)中产生细胞毒性活性氧(ROS)来根除肿瘤。为了克服目前使用的ps的缺点,研究人员利用生物正交反应的优势,设计了多种具有优异肿瘤选择性、高ROS生成可控性、低不良反应的生物正交活化光敏剂,用于有效的抗肿瘤光动力治疗。本文综述了生物正交活化光敏剂的结构类型、设计策略、活化模式、光物理性质、ROS生成效率、体内外活性、生物应用及局限性等方面的研究进展。我们还为解决生物正交活化光敏剂的治疗挑战提供了方向和观点,以促进临床应用。我们相信本文总结的原理将为进一步开发下一代先进智能光敏剂及相关策略,实现精准高效的肿瘤治疗提供有益的参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信